PD-L1 antibody (AA 181-230)

Catalog No. ABIN7227724

This Rabbit Polyclonal antibody specifically detects PD-L1 in IHC, ELISA and IF. It exhibits reactivity toward Human and Mouse.

Quick Overview for PD-L1 antibody (AA 181-230) (ABIN7227724)

Target: PD-L1 (CD274 (PD-L1))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PD-L1 antibody is un-conjugated

Application: Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF)

Product Details anti-PD-L1 Antibody

Binding Specificity: AA 181-230

Purpose: Rabbit Anti-CD274 Polyclonal Antibody

Specificity: The antibody detects endogenous levels of CD274

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Immunogen: Synthesized peptide derived from part region of human CD274 protein at AA range: 181-230

Isotype: IgG

Application Details

Application Notes: Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC 1:50-200,ELISA 1:10000-20000,IF 1:100-300,Not yet tested in other applications.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Expiry Date: 12 months

Target Details for PD-L1

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: CD274

Background: Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD antigen CD274CD274, also commonly referred to as PDL1, is a ligand that binds with the receptor PD1, commonly found on T-cells, and acts to block T-cell activation. PD1 expression has been observed in a variety of cancers including melanoma and non-small cell lung cancer. The interaction of PD1/PDL1 is hypothesized to be a possible mechanism for the tumor to escape immune response. A number of checkpoint blockade inhibitors including pembrolizumab and nivolumab have been developed that target the PD1/PDL1 interaction in order to allow T-cells to recognize tumor cells without being deactivated by the tumor.

Gene ID: 29126

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints